ABT Stock Chart & Fundamental Analysis

Interactive Chart

About Abbott Laboratories

Name

Abbott Laboratories

CEO

Robert Ford

Website

www.abbott.com

Industry

Healthcare

Year Founded

1888

Employees

114,000

Abbott Laboratories is a healthcare company focused on diagnostics, medical devices, nutrition, and branded generic medicines. Its product offerings range from glucose monitoring systems and cardiovascular devices to infant formula and adult nutrition products. The company’s diagnostics division supplies laboratories and hospitals with testing platforms that support disease detection and management. Abbott also provides branded generics in emerging markets, expanding access to affordable healthcare. With a presence across North America, Europe, Asia, and Latin America, the company operates within the healthcare sector, supporting both developed and developing markets with products designed to improve patient outcomes and quality of life.

Analyst Ratings

Consensus Recommendation

Buy3

Hold4

Sell14

Fundamentals & Financials

Revenue (TTM)

$43.8B

Net Income (TTM)

$13.9B

EPS (TTM)

$8.05

ROA (TTM)

16.6%

Current Ratio

1.7

Dividend Yield

0.1%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement (Quarterly)

Item	Q3 2025	Q2 2025	Q1 2025
Revenue	$11,369M	$11,142M	$10,358M
Cost of Sales	$5,031M	$4,854M	$4,914M
Gross Profit	$6,338M	$6,288M	$5,444M
Operating Income	$2,030M	$2,052M	$1,688M
Net Income	$1,644M	$1,779M	$1,325M
EPS	$0.94	$1.02	$0.76

Balance Sheet (Quarterly)

Financial Highlights (Quarterly)

Dividends History

Split History

Earnings Calendar (Quarterly)

Technical Indicators

Abbott Laboratories's Technical Indicators Summary

As of January 20th, ABT exhibits a bearish outlook with the current price trading well below all major moving averages, including the 200-day SMA and EMA, which signals sustained downward pressure. Momentum indicators such as the MACD and CCI reinforce this negative trend, showing selling momentum, while the RSI remains near oversold levels, suggesting limited buying interest. The trend strength appears weak, as reflected by a subdued ADX reading, indicating the bearish move lacks strong conviction. Despite this, volatility remains moderate, with the ATR signaling steady price fluctuations. Volume trends, evidenced by declining OBV, further support the bearish stance. Overall, ABT’s technical profile points to continuing weakness with no immediate signs of reversal.

Buy

3 signals

Neutral

4 signals

Sell

14 signals

Overall: Bearish67% Bearish signals

Indicator	Value	Signal	Explanation
RSI (14)	36.96	Neutral	RSI (36.96) is neutral.
Stochastic %K (14, 3, 3)	19.89	Buy	Stochastic (19.89) < 20, indicating oversold.
CCI (20)	-202.83	Sell	CCI (-202.83) < -100, indicating strong downward momentum.
WPR (14)	-97.22	Buy	Williams %R (-97.22) < -80, indicating oversold.
Momentum (10)	-2.43	Sell	Momentum (-2.43) is negative.
MFI	42.15	Neutral	MFI (42.15) is neutral.
MACD Level (12, 26)	-0.59	Sell	Confirmed downtrend: MACD (-0.59) is negative and below its signal line (-0.28).
Bollinger Bands	$122.55 - $127.69	Buy	Price ($121.76) is below the lower band ($122.55).
ATR (14)	$2.24 (1.84%)	Neutral	Moderate Volatility (1.84%).
ADX (14)	11.42	Neutral	Weak or consolidating trend (ADX < 25). ADX(11.42), +DI(17.51), -DI(25.68)
OBV	107,434,900	Sell	Bearish volume pressure: OBV is below its 20-day SMA. OBV(107,434,900), 20D-SMA-OBV(130,823,365)
Simple Moving Averages	$125.12 - $129.88(5 indicators)	Sell	The current price ($121.76) is below all key SMA levels (10, 20, 50, 100, and 200 periods), indicating a bearish trend across short to long-term moving averages.
Exponential Moving Averages	$124.46 - $128.90(5 indicators)	Sell	Price at $121.76 is below all key EMA levels (10, 20, 50, 100, 200), indicating a bearish trend across short to long-term moving averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

The new session started on a slightly positive note as ABT opened 0.471% higher at 121.71 versus 121.14. The opening tone includes an earnings overhang, as ABT reports in 1 days on 2026-01-22, trading near 121.51. Abbott's recent CE mark approval for the TactiFlex Duo could boost investor confidence amid ongoing sector advancements.

Price Change

from $121.14 close

+$0.37

Trading Volume

Below avg (7.2M)

2.5M

vs S&P 500 Today

Moderate Underperformance

-0.49%

52-Week Position

Lower range

28.9%